Synthesis and Preliminary Antiviral Activities of Piperidine‐substituted Purines against HIV and Influenza A/H1N1 Infections

We have developed a series of N2‐(1‐(substituted‐aryl)piperidin‐4‐yl)‐N6‐mesityl‐9H‐purine‐2,6‐diamine derivatives as potent antiviral agents. Preliminary biological evaluation indicated that nearly half of them possessed remarkable HIV inhibitory potencies in cellular assays. In particular, FZJ13 appeared to be the most notable one, which displayed anti‐HIV‐1 activity compared to 3TC. Moreover, an unexpected finding was that FZJ05 displayed significant potency against influenza A/H1N1 (strain A/PR/8/34) in Madin–Darby canine kidney cells with EC50 values much lower than those of ribavirin, amantadine, and rimantadine. The results suggest that these novel purine derivatives have the potential to be further developed as new therapeutic agents against HIV‐1 or influenza virus.

[1]  R. Gallo,et al.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.

[2]  F. Brun-Vézinet,et al.  Isolation of a new human retrovirus from West African patients with AIDS. , 1986, Science.

[3]  H. Klenk,et al.  Overexpression of the α-2,6-Sialyltransferase in MDCK Cells Increases Influenza Virus Sensitivity to Neuraminidase Inhibitors , 2003, Journal of Virology.

[4]  C. Pannecouque,et al.  Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later , 2008, Nature Protocols.

[5]  J. Jekő,,et al.  Anti-influenza virus activity and structure–activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains , 2009, Antiviral Research.

[6]  Peng Zhan,et al.  Design strategies of novel NNRTIs to overcome drug resistance. , 2009, Current medicinal chemistry.

[7]  Peng Zhan,et al.  Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. , 2009, Current medicinal chemistry.

[8]  Xiaohong Liu,et al.  Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. , 2010, Journal of medicinal chemistry.

[9]  L. Naesens,et al.  Novel Inhibitors of Influenza Virus Fusion: Structure-Activity Relationship and Interaction with the Viral Hemagglutinin , 2010, Journal of Virology.

[10]  Hong Lu,et al.  Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2010, Journal of medicinal chemistry.

[11]  Xianfeng Lin,et al.  Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. , 2010, Bioorganic & medicinal chemistry letters.

[12]  Hong Lu,et al.  Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2010, Journal of medicinal chemistry.

[13]  E. De Clercq,et al.  Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. , 2011, Current medicinal chemistry.

[14]  Peng Zhan,et al.  Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 – 2010) , 2011, Expert opinion on therapeutic patents.

[15]  Peng Zhan,et al.  Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. , 2012, Bioorganic & medicinal chemistry.

[16]  Peng Zhan,et al.  Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. , 2012, Journal of medicinal chemistry.

[17]  M. Wainberg,et al.  Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors , 2012, Antimicrobial Agents and Chemotherapy.

[18]  E. De Clercq,et al.  Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents , 2012, Archives of Pharmacal Research.

[19]  Bingjie Qin,et al.  Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. , 2012, Journal of medicinal chemistry.

[20]  Peng Zhan,et al.  Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. , 2013, Bioorganic & medicinal chemistry.

[21]  Huiqing Liu,et al.  Discovery of Piperidine‐Linked Pyridine Analogues as Potent Non‐nucleoside HIV‐1 Reverse Transcriptase Inhibitors , 2013, ChemMedChem.

[22]  P. Zhan,et al.  Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. , 2013, Current pharmaceutical design.

[23]  Peng Zhan,et al.  HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design , 2013, Medicinal research reviews.

[24]  Peng Zhan,et al.  Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. , 2014, Bioorganic & medicinal chemistry.

[25]  Peng Zhan,et al.  Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. , 2014, European journal of medicinal chemistry.

[26]  Peng Zhan,et al.  Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011 – 2014) , 2014, Expert opinion on therapeutic patents.

[27]  E. De Clercq,et al.  Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. , 2014, European journal of medicinal chemistry.

[28]  Peng Zhan,et al.  Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. , 2014, European journal of medicinal chemistry.

[29]  Peng Zhan,et al.  Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. , 2014, Bioorganic & medicinal chemistry.

[30]  Peng Zhan,et al.  Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. , 2014, European journal of medicinal chemistry.

[31]  Peng Zhan,et al.  "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets. , 2014, Molecular bioSystems.

[32]  Peng Zhan,et al.  "Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refining. , 2014, Combinatorial chemistry & high throughput screening.

[33]  Peng Zhan,et al.  Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update. , 2013, Current medicinal chemistry.

[34]  E. De Clercq,et al.  Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. , 2015, European journal of medicinal chemistry.